A novel cell immunoassay to measure survival of motor neurons protein in blood cells by Kolb, Stephen J et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Neurology
Open Access Research article
A novel cell immunoassay to measure survival of motor neurons 
protein in blood cells
Stephen J Kolb1, Amelie K Gubitz1, Robert F Olszewski Jr1, 
Elizabeth Ottinger1, Charlotte J Sumner2, Kenneth H Fischbeck2 and 
Gideon Dreyfuss*1
Address: 1Howard Hughes Medical Institute And Department of Biochemistry & Biophysics, University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania, 19104-6148, USA and 2Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 
20892, USA
Email: Stephen J Kolb - skolb@mail.med.upenn.edu; Amelie K Gubitz - gubitza@ncbi.nlm.nih.gov; 
Robert F Olszewski - robert.olszewski@jefferson.edu; Elizabeth Ottinger - ottingea@mail.med.upenn.edu; 
Charlotte J Sumner - sumnerc@ninds.nih.gov; Kenneth H Fischbeck - fischbeck@ninds.nih.gov; 
Gideon Dreyfuss* - gdreyfuss@hhmi.upenn.edu
* Corresponding author    
Abstract
Background: The motor neuron degenerative disease spinal muscular atrophy (SMA) is the
leading genetic cause of infant mortality and is caused by mutations in the survival of motor neurons
(SMN) gene that reduce the expression levels of the SMN protein. A major goal of current
therapeutic approaches is to increase SMN levels in SMA patients. The purpose of this study was
to develop a reliable assay to measure SMN protein levels from peripheral blood samples.
Methods: We developed a novel cell immunoassay to quantitatively measure SMN levels from
peripheral blood mononuclear cells (PBMCs) using a single anti-SMN antibody.
Results: SMN levels determined by the cell immunoassay are comparable to levels determined by
Western blot, but in contrast, the immunoassay does not involve cell lysis, requires a small amount
of patient material, and can be done on a large number of samples simultaneously. SMN levels from
PBMCs are not influenced by cell type heterogeneity.
Conclusion: SMN levels measured from total PBMCs provide an important snapshot of SMN
protein expression, which should be a useful aid in SMA diagnosis, and a surrogate marker of
efficacy of treatment in SMA clinical trials.
Background
Spinal muscular atrophy (SMA) is one of the most com-
mon autosomal recessive diseases, affecting approxi-
mately 1 in 6,000 to 10,000 live births, and is the leading
hereditary cause of infant mortality [1,2]. SMA is a neuro-
degenerative disease of motor neurons that results in pro-
gressive muscle weakness and death from respiratory
failure, and is caused by mutations in the survival of
motor neurons (SMN) gene [3]. These mutations result in
a reduction in SMN protein expression and several studies
have shown that SMN protein levels are reduced in cell
lines and tissues derived from type I SMA patients com-
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pared to controls [4-7]. An obvious therapeutic strategy
for this disease is, therefore, to attempt to increase SMN
expression levels.
In recent years, several drugs have been shown to increase
SMN mRNA and/or protein levels in cultured cells [8-16].
As a result, many of these compounds currently are, or are
planned to be, in clinical trials. The design of therapeutic
clinical trials for SMA patients hinges upon the expecta-
tion that survival or objective improvement in phenotype
will be achieved. These benefits, if they are to occur, are
long-term outcomes [17]. Thus, there is a need for bio-
chemical surrogate assays to determine whether SMN lev-
els are affected in patients that receive such treatments.
SMN mRNA has been measured in blood by quantitative
RT-PCR in a small number of patients in one previous
study [18], however RT-PCR requires amplification of
patient material and mRNA levels do not necessarily cor-
relate with the amount of protein expressed in the cells.
We have developed a cell immunoassay to measure SMN
levels in peripheral blood samples. We further compare
this assay with the standard Western blot method for
quantifying SMN protein and show that this method is
feasible for use with patient blood samples during clinical
trials.
Methods
Cell lines
Lymphoblastoid cell lines GM12497 (derived from a 7
month old control patient) and GM10684 (derived from
a 6 month old type I SMA patient) were purchased from
Coriell Cell Repositories (New Jersey) and maintained in
RPMI media with 10% fetal bovine serum.
Subjects and blood draws
Blood samples from anonymous, control individuals
were collected in the department of transfusion medicine
at the NIH as part of an NIH IRB approved protocol.
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by standard Ficoll density gradient centrifugation,
resuspended in fetal bovine serum with 10% DMSO and
were cryopreserved. Pooled monocytes and lymphocytes
were also obtained from the department of transfusion
medicine at the NIH. Cells were then sent by overnight
courier to the University of Pennsylvania on dry ice for
protein level determination.
Western blot
The anti-SMN (62E7) and anti-Y14 (1F12) monoclonal
antibodies have been described previously [19,20]. The
anti-mouse IgG secondary antibody labeled with IRDye
®800 (Rockland) was used at 1:5000. Proteins from 20 μg
of total extracts were separated on NuPAGE® 4–12% Bis-
Tris gels (Invitrogen) and transferred to nitrocellulose
membranes. Quantitative immunoblotting was per-
formed as suggested by the manufacturer (Li-Cor). The
membranes were scanned on an Odyssey® infrared imag-
ing system (Li-Cor), and the intensity of the protein bands
was analyzed using the software provided by the manufac-
turer.
Surrogate SMN level cell immunoassay
Cell immunoassays to determine SMN protein levels were
performed using black, clear-bottomed 96-well plates pre-
coated with poly-ornithine (Sigma M0562). Immediately
before the assay, cryopreserved PBMC samples were
thawed, washed in phosphate-buffered saline (PBS) and
counted with an automated NucleoCounter cell counter
(New Brunswick Scientific). 1.5 × 105  cells/well were
adhered to the well bottom by centrifugation (700 × g) for
5 minutes at room temperature. The cells were then fixed
to the plate with 2.5% formaldehyde for 30 min and
washed in PBS. All washes were performed with PBS using
a Biotek ELX405 automatic plate washer. Cells were per-
meabilized with 0.1% Triton for 5 min and blocked with
20% FBS for 1 hour. The antibody used for the immuno-
sorbant assay was monoclonal antibody 2B1 (1:500)
against SMN. The plates were washed, and bound anti-
bodies were detected using peroxidase-conjugated goat
anti-mouse IgG (Jackson ImmunoResearch) and Supersig-
nal® ELISA Femto Maximum Sensitivity Substrate (Pierce).
The luminescent intensity within each well was measured
using a Perkin Elmer Victor2 plate reader. Signal back-
ground was determined for each sample by omitting the
primary antibody.
Statistical analysis
All error bars are standard deviation from the mean. The
cell number titration data was fitted to a sigmoid curve
using IGor.
Results and discussion
We have developed a simple cell immunoassay to deter-
mine SMN protein levels that can be performed in 96-well
plates and potentially higher density formats. To assess
the influence of various parameters, we used a lymphob-
lastoid cell line derived from a type I SMA patient
(GM10684) and a similarly established cell line from an
age- and gender-matched individual as a control
(GM12497) that we have previously characterized [21].
For each experiment, the common exon-junction complex
component protein Y14 was also determined to confirm
equal loading of wells. As expected, SMN levels in patient
cells were significantly reduced compared to control (Fig-
ure 1A). When expressed as a ratio of SMN to Y14 expres-
sion, control SMN levels were 5.31 ± 0.04 and SMA I levels
were 2.21 ± 0.05(N = 4). The optimal number of patient
lymphoblastoid cells to load into a 96-well plate well,
determined for this assay, was 1.5 × 105 cells (Figure 1B).BMC Neurology 2006, 6:6 http://www.biomedcentral.com/1471-2377/6/6
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Immunoblotting performed at the same time confirmed
that SMN levels in the patient cells were reduced (Figure
1C and 1D). The degree of reduction in SMN protein
measured by the 96-well plate-based assay (58.3 ± 7.0%,
N = 4) was comparable to that measured by Western blot
(66.8 ± 10.7%, N = 9).
Blood samples are the most practical source of patient
cells for SMN protein level determination and can be
measured repeatedly over time. We chose to study the
peripheral blood mononuclear cells (PBMC) because they
are readily isolated and typically represent the physiolog-
ical cellular environment. One potential source of varia-
bility of using the PBMC is cell type heterogeneity, which
can vary between different individuals and within the
same individual at different times. We therefore compared
SMN levels in pure populations of human monocytes and
lymphocytes and found no significant difference when
the same number of cells was analyzed (Figure 2A). More-
over, mixing the cell types had no effect on the SMN or
Y14 levels. SMN levels from peripheral blood of control
individuals are shown in Figure 2B. The intensity values
for SMN and Y14 in PBMCs are similar in the pure and
mixed monocyte and lymphocyte populations.
The SMN protein cell immunoassay compares SMN
expression in an equivalent number of PBMC cells and
does not depend on a stable endogenous control. None-
theless, the use of Y14 as a stable endogenous control in
these experiments, as would be done for Western blot
analysis, lends further confidence in the assay to detect
specific changes in SMN expression between two well-
characterized cell lines. The SMN protein cell immu-
noassay method does not require cell lysis as do western
blotting and sandwich ELISA methods. Moreover, there is
no transfer of protein to a membrane and a relatively
A) SMN levels in control and SMA I lymphoblastoid cell lines from four separate experiments Figure 1
A) SMN levels in control and SMA I lymphoblastoid cell lines from four separate experiments. B) SMN and Y14 chemilumines-
cent intensity levels as a function of number of cells loaded per 96-well plate well. C) SMN levels from the same cell lines 
determined by Western blot. D) Quantification of Western blot data N = 9. Error bars are standard deviation from the mean.
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small amount of biological sample is required. We find
that SMN levels can be measured in triplicate from a 5 to
8 ml sample of peripheral blood.
Nucleated cells from blood were chosen for protein deter-
minations because the SMN protein is found both in the
cytoplasm and the nucleus of cells. The measurement of
SMN in the PBMC is valid despite the fact that the cell type
composition of the PBMC can vary between individuals
and even within the same individual at different times.
We addressed the issue of cell type heterogeneity by meas-
uring SMN in pure populations of PBMC components
and found no effect of cell type composition. Recently, we
also described a reliable assay to measure a well estab-
lished function of the SMN protein, small nuclear ribonu-
cleoprotein (snRNP) assembly [21,22]. In combination,
the SMN protein cell immunoassay, described here, with
the SMN activity assay can be used to gain insight into the
regulation of SMN protein expression and activity. These
new assays may significantly add to the present methods
available to study SMA.
Conclusion
We describe a simple cell immunoassay to measure SMN
levels in peripheral blood samples. This assay requires a
small amount of patient material and can be done on a
large number of samples simultaneously. The ability to
measure SMN levels from peripheral blood samples pro-
vides an important snapshot of SMN expression that can
be used as a surrogate outcome measure in ongoing and
future SMA clinical trials.
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